Australia | AI-powered Medical Devices: Tipping the scales in favour of patent eligibility
Key takeaways The Australian regulatory framework for medical devices provides useful, practical guidance for patenting inventions involving Artificial Intelligence (AI) within the medical technology (medtech) space. Whilst there is no statutory...
Key takeaways The Australian regulatory framework for medical devices provides useful, practical guidance for patenting inventions involving Artificial Intelligence (AI)...
Read More
China | Establishing Inventive Step in Swiss-Type Use Claims – A Case Study on Disease Subtypes and Known APIs
As pharmaceutical innovation increasingly targets specific disease subtypes and personalised therapies, patent protection strategies must evolve accordingly—especially in jurisdictions like China, where method of treatment claims are not patentable. This...
As pharmaceutical innovation increasingly targets specific disease subtypes and personalised therapies, patent protection strategies must evolve accordingly—especially in jurisdictions...
Read More
Can patient data be used to train AI?
Key takeaways Inventors and Applicants need to ensure that the data used to support their patent applications comply with relevant laws relating to the use of patient data, such as...
Key takeaways Inventors and Applicants need to ensure that the data used to support their patent applications comply with relevant...
Read More
China | Good faith principle for patent applications
The principle of ‘good faith’ plays a crucial role in ensuring the integrity and reliability of patent applications. This principle is particularly emphasised in China's patent law, where adherence...
The principle of ‘good faith’ plays a crucial role in ensuring the integrity and reliability of patent applications. This...
Read More
China | Recent updates on post-filing data for patent applications
In China's patent examination practice, the technical effects demonstrated by experimental data are a crucial factor for patent applications, especially for biotech and chemical inventions. In order to address objections...
In China's patent examination practice, the technical effects demonstrated by experimental data are a crucial factor for patent applications,...
Read More
Skinny labelling in the Australian context: an overview
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be protected by several different patent claim formats, including method of...
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be...
Read More
Pharmaceutical patent term extension in Australia
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial importance, and in recent years have become of particular interest...
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial...
Read More
Federal Budget 24-25 “Future Made in Australia” features for cleantech
Treasurer Jim Chalmers delivered his third Federal Budget on Tuesday, 14 May 2024, featuring the promised details and costings of the recently announced Future Made in Australia Act, and...
Treasurer Jim Chalmers delivered his third Federal Budget on Tuesday, 14 May 2024, featuring the promised details and costings...
Read More